PRILOcaine for Cervical Cerclage trial (PRILOCC trial)
Research type
Research Study
Full title
Does subarachnoid administration of hyperbaric prilocaine produce an improved recovery from anaesthesia when compared with hyperbaric bupivacaine when used to make cervical cerclage easier in pregnant women at risk of pre-term loss?
IRAS ID
225703
Contact name
Neel Desai
Contact email
Sponsor organisation
Guy's & St Thomas' Foundation NHS Trust R&D Department
Eudract number
2019-001548-23
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Cervical cerclage is a procedure that is carried out as a day case procedure in order to prevent preterm loss in at risk pregnancies. The anaesthetic used to facilitate this varies widely across the United Kingdom. Most centres use regional anaesthesia to avoid exposing the foetus to general anaesthetic drugs but it can be difficult to achieve discharge on the same day due to residual leg weakness and lack of bladder control. On occasions patients require urinary catheterization and admission to hospital.
Prilocaine is a commonly used drug which has a shorter duration of action than bupivacaine which is the more commonly used drug for spinal anesthesia. Although prilocaine is used in the context of cervical cerclage, it is more expensive and there is no data to document that it has a significant advantage over bupivacaine.
This study aims to compare the recovery profiles of equivalent doses of prilocaine and bupivacaine when administered by the intrathecal route to facilitate cervical cerclage. The main outcomes to be assessed will be time to return of leg movement, ability to pass urine, need for catheterization and discharge from hospital.
REC name
London - Central Research Ethics Committee
REC reference
20/LO/0231
Date of REC Opinion
2 Apr 2020
REC opinion
Favourable Opinion